

Financial news for CPHD dated on 2016-10-24: Cepheid Reports Receipt of Required Regulatory Clearances in Proposed Acquisition by Danaher Corporation

Financial news for CPHD dated on 2016-10-04: Novacyt Signs Strategic Alliance with Cepheid for HPV Diagnostics in Latin America

Financial news for CPHD dated on 2016-09-26: Proxy Statement Shows Danaher Faced Competition In Bid To Buy Cepheid

Financial news for CPHD dated on 2016-09-15: Cepheid Reports Expansion of Binary Toxin Gene Reporting, Added to Xpert C. Difficile Portfolio

Financial news for CPHD dated on 2016-09-12: Benzinga's Top Downgrades

Financial news for CPHD dated on 2016-09-12: Baird Downgrades Cepheid to Neutral

Financial news for CPHD dated on 2016-09-08: 7 Biggest Price Target Changes For Thursday

Financial news for CPHD dated on 2016-09-08: Citigroup Downgrades Cepheid to Neutral, Raises PT to \$53.00

Financial news for CPHD dated on 2016-09-07: BTIG Sees Another Bidder For Cepheid 'Unlikely'

Financial news for CPHD dated on 2016-09-07: Benzinga's Top Downgrades

Financial news for CPHD dated on 2016-09-07: BTIG Research Downgrades Cepheid to Neutral

Financial news for CPHD dated on 2016-09-07: Cowen & Company Downgrades Cepheid to Market Perform

Financial news for CPHD dated on 2016-09-06: Benzinga's M&A Chatter for Tuesday September 6, 2016

Financial news for CPHD dated on 2016-09-06: Tuesday's Market Wrap: Stocks Start Shortened Week With Moderate Gains

Financial news for CPHD dated on 2016-09-06: Cepheid Announces FDA To Allow Expanded Claims For The Xpert TV Assay Urine Test

Financial news for CPHD dated on 2016-09-06: Mid-Afternoon Market Update: Gold Futures Up 2%; CoLucid Shares Climb After Migraine Drug Achieves Primary And Key Secondary Endpoints

Financial news for CPHD dated on 2016-09-06: 12 Biggest Mid-Day Gainers For Tuesday

Financial news for CPHD dated on 2016-09-06: Craig-Hallum Downgrades Cepheid to Hold

Financial news for CPHD dated on 2016-09-06: Mid-Day Market Update: Navistar Rises After Strategic Alliance With Volkswagen Truck & Bus; Tonix Shares Drop

Financial news for CPHD dated on 2016-09-06: Benzinga's Volume Movers

Financial news for CPHD dated on 2016-09-06: Mid-Morning Market Update: Markets Open Higher; Danaher To Acquire Cepheid For \$4B

Financial news for CPHD dated on 2016-09-06: Needham Downgrades Cepheid to Hold

Financial news for CPHD dated on 2016-09-06: PiperJaffray Downgrades Cepheid to Neutral

Financial news for CPHD dated on 2016-09-06: The Market In 5 Minutes: Stocks Return Higher From Three-Day Weekend

Financial news for CPHD dated on 2016-09-06: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CPHD dated on 2016-09-06: A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Economic Data

Financial news for CPHD dated on 2016-09-06: Danaher To Buy Cepheid For \$4 Billion

Financial news for CPHD dated on 2016-09-06: Cepheid To Be Acquired By Danaher For \$53/Share

Financial news for CPHD dated on 2016-07-28: Cepheid Sees FY16 Adj. EPS \$0.31-\$0.34 vs \$0.25 Est., Sales \$618M-\$635M vs \$621.7M Est.

Financial news for CPHD dated on 2016-07-28: Cepheid Reports Q2 Adj. EPS \$0.05 vs \$0.00 Est., Sales \$146M

Financial news for CPHD dated on 2016-07-12: Cepheid Reports Results Of Validation Study For Use Of Xpert HPV In Primary Cervical Cancer Screening

Financial news for CPHD dated on 2016-06-29: FDA Has Cleared Cepheid's Xpert Carba-R Assay

Financial news for CPHD dated on 2016-06-17: Analysts Give Healthcare Sector A Clean Bill Of Health

Financial news for CPHD dated on 2016-06-15: Cepheid Margin Expansion Unlikely To Morgan Stanley, Stays On Sidelines

Financial news for CPHD dated on 2016-06-15: Benzinga's Top Initiations

Financial news for CPHD dated on 2016-06-15: Cepheid Reports WHO Prequalification of Xpert HIV-1 Qualitative Test

Financial news for CPHD dated on 2016-06-15: Morgan Stanley Initiates Coverage on Cepheid at Equal-weight, Announces \$30.00 PT

Financial news for CPHD dated on 2016-04-29: Mid-Afternoon Market Update: NASDAQ Down Over 1%; SkyWest Shares Jump On Earnings Beat

Financial news for CPHD dated on 2016-04-29: Mid-Day Market Update: Amazon Surges On Upbeat Results; ImmunoGen Shares Decline

Financial news for CPHD dated on 2016-04-29: Mid-Morning Market Update: Markets Open Lower; Exxon Mobil Profit Tops Estimates

Financial news for CPHD dated on 2016-04-28: Cepheid Sees FY16 Rev. \$618-\$635M vs. Est. \$622M, EPS \$0.22-\$0.28 vs. Est. \$0.24

Financial news for CPHD dated on 2016-04-28: Cepheid Reports Q1 EPS \$0.08 vs. Est. \$0.01, Rev. \$144.8M vs. Est. \$140M

Financial news for CPHD dated on 2016-04-21: Cepheid Announces Partner Distribution Agreement With Medline, no terms

Financial news for CPHD dated on 2016-04-01: Benzinga's Top Upgrades

Financial news for CPHD dated on 2016-04-01: BTIG Research Upgrades Cepheid to Buy, Announces \$42.00 PT

Financial news for CPHD dated on 2016-03-29: Cepheid Announces European Approval Of Xpert MRSA Next Generation Screening Test

Financial news for CPHD dated on 2016-03-09: Cepheid Reports First FDA-Cleared Test for Detection for Carbapenem Resistance Genes in Isolates of Multidrug Resistant Superbugs

Financial news for CPHD dated on 2016-02-10: Cepheid Names Warren Kocmond as Pres, COO

Financial news for CPHD dated on 2016-02-02: Cepheid Reports Rev. \$618-\$635M vs. Est. \$622.43M, EPS \$(0.57)-\$(0.51) vs. Est. \$(0.48)

Financial news for CPHD dated on 2016-02-02: Cepheid Reports Q4 EPS (\$0.14) vs. Est. (\$0.20), Rev. \$147M vs. Est. \$146.91M

Financial news for CPHD dated on 2016-01-13: Cepheid Announces Diagnostic Collaboration With MedImmune And COMBACTE To Facilitate Clinical Trials Of New Monoclonal Antibodies To Prevent Serious Infectious Diseases

Financial news for CPHD dated on 2016-01-07: USAID, Cepheid Plan Partner To Accelerate Global Diagnosis Of Multidrug-Resistant Tuberculosis

Financial news for CPHD dated on 2016-01-06: Avondale Partners Initiates Coverage on Cepheid at Market Outperform, Announces \$46.00 PT

Financial news for CPHD dated on 2016-01-04: Cepheid Reports Distribution Deal with Henry Schein Medical for GeneXpert System, Menu of 17 Xpert Tests

Financial news for CPHD dated on 2015-12-17: Benzinga's Top Upgrades

Financial news for CPHD dated on 2015-12-17: Needham Upgrades Cepheid to Buy

Financial news for CPHD dated on 2015-12-08: Cepheid Reports Intl. Availability Of BCR-ABL Test

Financial news for CPHD dated on 2015-12-07: Cepheid Receives FDA CLIA Waiver for Xpert Flu+RSV Xpress Test

Financial news for CPHD dated on 2015-12-03: FIND And Cepheid Announce A Strategic Collaboration To Advance Point-Of-Care TB Diagnosis

Financial news for CPHD dated on 2015-12-02: Benzinga's Top Downgrades

Financial news for CPHD dated on 2015-12-02: Wells Fargo Downgrades Cepheid to Market Perform

Financial news for CPHD dated on 2015-12-01: 15 Biotechs Making Announcements At The 2015 Piper Jaffray Healthcare Conference

Financial news for CPHD dated on 2015-12-01: Cepheid Reaffirms FY15 EPS \$(0.73)-\$(0.71) vs \$(0.58) Est., Sales \$537M-\$541M vs \$538.6M Est.

Financial news for CPHD dated on 2015-12-01: Cepheid Sees FY16 Rev. \$618-\$635M vs. Est. \$619.74M

Financial news for CPHD dated on 2015-12-01: Cepheid Reaffirms Q4 Rev. \$146-\$150M vs. Est. \$147.01M, EPS (\$0.19)-(\$0.17) vs. Est. (\$0.19)

Financial news for CPHD dated on 2015-11-12: Stifel Nicolaus Initiates Coverage on Cepheid at Buy, Announces \$42.00 PT

Financial news for CPHD dated on 2015-10-21: Stocks Hitting 52-Week Lows

Financial news for CPHD dated on 2015-10-21: Mid-Morning Market Update: Markets Mostly Flat; General Motors Earnings Top Expectations

Financial news for CPHD dated on 2015-10-21: Benzinga's Top Downgrades

Financial news for CPHD dated on 2015-10-21: Cepheid Receives FDA Clearance for Xpert TV, the First On-Demand Test for Same Day Consultation and Treatment of Trichomonas Vaginalis Infection

Financial news for CPHD dated on 2015-10-21: Canaccord Genuity Downgrades Cepheid to Hold

Financial news for CPHD dated on 2015-10-20: Cepheid Sees FY15 Adj. Loss of \$0.01 to Gain of \$0.01/Share, GAAP Loss of \$0.73-\$0.71/Share vs Loss of \$0.63/Share Est., Sales \$537M-\$541M vs \$539M Est.

Financial news for CPHD dated on 2015-10-20: Cepheid Reports Q3 Adj Loss \$0.13 Vs Est Loss \$0.31, Sales \$126.5M Vs Est \$126.81M

Financial news for CPHD dated on 2015-10-14: Mid-Afternoon Market Update: Colfax Drops On Weak Results; SanDisk Shares Jump

Financial news for CPHD dated on 2015-10-14: Mid-Day Market Update: Dow Drops Over 100 Points; TripAdvisor Shares Surge Following Announcement of Partnership With Priceline

Financial news for CPHD dated on 2015-10-14: Stocks Hitting 52-Week Lows

Financial news for CPHD dated on 2015-10-14: Mid-Morning Market Update: Markets Gain; Bank of America Earnings Top Views

Financial news for CPHD dated on 2015-10-14: Morning Market Losers

Financial news for CPHD dated on 2015-10-14: Cepheid Sells Off on Heavy Volume

Financial news for CPHD dated on 2015-10-14: Benzinga's Top #PreMarket Losers

Financial news for CPHD dated on 2015-10-13: Tuesday's After-Hours Movers Led By SanDisk, Cepheid, JPMorgan & CSX

Financial news for CPHD dated on 2015-10-13: Cepheid Sees Q4 Revs \$146M-\$150M Vs Est \$156.36M; Sees FY Revs \$537M-\$541M Vs Est \$549.40M

Financial news for CPHD dated on 2015-10-13: UPDATE: Cepheid Sees Q3 Sales Slightly Below Street Estimate

Financial news for CPHD dated on 2015-10-13: Cepheid Reports Q3 Prelims Loss \$0.13 Vs

Est Loss \$0.26, Sales \$126.5M Vs Est \$127.82M

Financial news for CPHD dated on 2015-10-13: Cepheid Sees Q3 Loss Better Than Expected

Financial news for CPHD dated on 2015-08-13: Cepheid CFO Ilan Daskal Announces Departure; Names Dan Madden EVP, CFO

Financial news for CPHD dated on 2015-07-24: Morning Market Losers

Financial news for CPHD dated on 2015-07-24: Benzinga's Top Downgrades

Financial news for CPHD dated on 2015-07-24: Evercore Partners Downgrades Cepheid to Sell

Financial news for CPHD dated on 2015-07-23: Cepheid Reports Q2 Loss of \$0.23/Share vs Loss of \$0.21/Share Est., Sales \$132.5M vs \$130.7M Est.; Sees FY15 Sales \$544M-\$553M vs \$551.3M Est., Adj. EPS \$0.25-\$0.29

Financial news for CPHD dated on 2015-06-26: Craig-Hallum Upgrades Cepheid To Buy

Financial news for CPHD dated on 2015-06-26: Benzinga's Top Upgrades

Financial news for CPHD dated on 2015-06-26: Craig-Hallum Upgrades Cepheid to Buy, Raises PT to \$75.00

Financial news for CPHD dated on 2015-04-24: Morning Market Gainers

Financial news for CPHD dated on 2015-04-23: Cepheid Expecting FY Loss of \$0.47-\$0.43/Share vs Loss of \$0.45/Share Est., Sales \$542M-\$553M vs \$547M Est.

Financial news for CPHD dated on 2015-04-23: Cepheid Reports Q1 EPS \$0.17 Vs Est -\$0.16 May Not Compare, Sales \$132.6M Vs Est \$125.40m

Financial news for CPHD dated on 2015-04-16: Cepheid, FIND Report European Approval of Xpert HIV-1 Qual

Financial news for CPHD dated on 2015-04-15: US Stock Futures Rise Ahead Of Earnings, Economic Data

Financial news for CPHD dated on 2015-04-15: Cepheid Announces European Approval of Xpert HCV Viral Load

Financial news for CPHD dated on 2015-04-07: Cepheid Names Ilan Daskal EVP, CFO

Financial news for CPHD dated on 2015-03-26: Goldman Sachs Cuts Myriad Genetics To Sell, Ups Alere

Financial news for CPHD dated on 2015-03-24: Cepheid Receives Emergency Use Authorization From FDA For Xpert Ebola Diagnostic Test

Financial news for CPHD dated on 2015-02-13: Novartis, Verastem & Cepheid Making Biotech Headlines On Friday

Financial news for CPHD dated on 2015-02-13: Cepheid Announces FDA Clearance for Expanded Claims for Xpert MTB/RIF Tuberculosis Test

Financial news for CPHD dated on 2014-12-29: Cepheid, FIND Report European Approval of Xpert HIV-1 Viral Load in Plasma, Says Delivers Individual Results in ~90 Mins

Financial news for CPHD dated on 2014-12-18: Benzinga's Top Upgrades

Financial news for CPHD dated on 2014-12-18: Bank of America Upgrades Cepheid To Buy

Financial news for CPHD dated on 2014-12-18: Bank of America Upgrades Cepheid to Buy, Raises PO to \$60.00

Financial news for CPHD dated on 2014-12-04: UPDATE: Citigroup Reiterates On Cepheid Following Positive Data

Financial news for CPHD dated on 2014-12-04: Citigroup Maintains Buy on CEPHEID, Raises PT to \$62.00

Financial news for CPHD dated on 2014-12-02: Oppenheimer Maintains Outperform on CEPHEID, Raises PT to \$57.00

Financial news for CPHD dated on 2014-12-01: Cepheid Receives FDA Clearance For Xpert Norovirus, The First On-Demand Molecular Test For Detection of Norovirus

Financial news for CPHD dated on 2014-11-24: Cepheid Receives FDA Clearance For Xpert Flu/RSV XC

Financial news for CPHD dated on 2014-11-13: Bank of America Maintains Neutral on CEPHEID, Raises PT to \$56.00

Financial news for CPHD dated on 2014-11-13: UPDATE: Cepheid Announces Will Develop Xpert Ebola Rapid Test, Receives Grant for Up to \$3.3M from Paul Allen, Gates Foundation

Financial news for CPHD dated on 2014-11-13: Cepheid Announces Will Develop Xpert Ebola Rapid Test, Receives Grant for Up to \$3.3M from Paul Allen, Gates Foundation

Financial news for CPHD dated on 2014-11-13: Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic

Financial news for CPHD dated on 2014-10-16: CEPHEID Sees FY2014 Adj. EPS \$0.11-0.13, GAAP Loss \$0.52-\$0.54/Share Range; Sees Sales \$461.0M-465.0M vs \$458.80M Est

Financial news for CPHD dated on 2014-10-16: CEPHEID Reports Q3 Non-GAAP EPS of \$0.06 Which May Not Compare \$(0.16) Est; Revenue of \$115.20M Which May Not Compare \$110.06M Est. GAAP EPS Was A Loss Of \$0.10

Financial news for CPHD dated on 2014-10-01: LABSCO Reaches Purchase Agreement With Cepheid For \$21M

Financial news for CPHD dated on 2014-10-01: Cepheid Extends Reach Of Direct US Commercial Operations

Financial news for CPHD dated on 2014-09-17: Cantor Fitzgerald Upgrades CEPHEID to Buy, Maintains \$52.00 PT

Financial news for CPHD dated on 2014-08-28: Option Alert: Cepheid Shares Spike Higher; Activity in Sep \$40 Call

Financial news for CPHD dated on 2014-08-11: UPDATE: ISI Group Upgrades Cepheid

Financial news for CPHD dated on 2014-08-11: ISI Group Upgrades CEPHEID to Neutral

Financial news for CPHD dated on 2014-07-17: CEPHEID Sees FY2014 Adj. EPS \$0.10-0.13, GAAP Loss of \$0.51-0.54/Share Which May Not Compare \$(0.37) Est; Sees Sales \$452.0M-461.0M Which May Not Compare \$460.13M Est

Financial news for CPHD dated on 2014-07-17: CEPHEID Reports Q2 EPS of \$(0.14) vs \$(0.13) Est; Revenue of \$116.50M vs \$115.47M Est

Financial news for CPHD dated on 2014-07-10: Wells Fargo Initiates Coverage on CEPHEID at Outperform

Financial news for CPHD dated on 2014-06-09: Craig-Hallum Upgrades CEPHEID to Hold

Financial news for CPHD dated on 2014-05-27: Needham Upgrades CEPHEID to Buy, Announces \$50.00 PT

Financial news for CPHD dated on 2014-04-17: CEPHEID Sees Q2 Sales \$113.0M-115.0M vs \$110.68M Est

Financial news for CPHD dated on 2014-04-17: CEPHEID Sees Fy EPS \$0.19-0.24 vs \$0.26 Est; Sees Sales \$446.0M-461.0M vs \$457.90M Est

Financial news for CPHD dated on 2014-04-17: CORRECTION: Cepheid Reports Q4 EPS of \$(0.01); Revenue of \$106.90M

Financial news for CPHD dated on 2014-04-17: Cepheid Reports Q4 EPS of \$0.01; Revenue of \$106.90M

Financial news for CPHD dated on 2014-04-10: Cepheid Announces Release of Xpert Norovirus in Europe

Financial news for CPHD dated on 2014-04-09: JMP Securities Upgrades CEPHEID to Market Outperform, Announces \$58.00 PT

Financial news for CPHD dated on 2014-04-02: Cepheid Announces European Release ff Xpert HPV 60-Minute Test for Cervical Cancer-Related Human Papillomaviruses

Financial news for CPHD dated on 2014-02-03: Cepheid To Offer \$250 Million Convertible Senior Notes Due 2021

Financial news for CPHD dated on 2014-01-30: CEPHEID Sees FY2014 EPS \$0.24-0.29 Which

May Not Compare \$0.01 Est; Sees Sales \$446.0M-461.0M Which May Not Compare \$447.50M Est

Financial news for CPHD dated on 2014-01-30: CEPHEID Reports Q4 EPS of \$0.03 vs \$(0.11) Est; Revenue of \$113.30M vs \$102.17M Est

Financial news for CPHD dated on 2013-12-19: Needham Initiates Coverage on CEPHEID at Market Perform

Financial news for CPHD dated on 2013-12-18: UPDATE: JMP Securities Initiates Coverage on Cepheid on Market Leader Position

Financial news for CPHD dated on 2013-12-18: JMP Securities Initiates Coverage on CEPHEID at Market Perform

Financial news for CPHD dated on 2013-12-12: Bank of America Maintains Neutral on CEPHEID, Raises PO to \$46.00

Financial news for CPHD dated on 2013-10-17: CEPHEID Sees FY2013 EPS \$(0.24)-(0.26) vs \$(0.26) Est

Financial news for CPHD dated on 2013-10-17: CEPHEID Reports Q3 EPS of \$0.09 vs \$(0.12) Est; Revenue of \$100.10M vs \$93.86M Est

Financial news for CPHD dated on 2013-10-10: SunTrust Robinson Humphrey Initiates Coverage on CEPHEID at Neutral, Announces \$38.00 PT

Financial news for CPHD dated on 2013-10-04: UPDATE: ISI Group Downgrades Cepheid on Key Drivers Constraining Revenue Multiple

Financial news for CPHD dated on 2013-10-04: Benzinga's Top Downgrades

Financial news for CPHD dated on 2013-10-04: ISI Group Downgrades CEPHEID to Sell, Raises PT to \$34.00

Financial news for CPHD dated on 2013-10-01: UPDATE: Bank of America Downgrades Cepheid on Fair Valuation

Financial news for CPHD dated on 2013-10-01: Benzinga's Top Downgrades

Financial news for CPHD dated on 2013-10-01: Bank of America Downgrades CEPHEID to Neutral, Raises PO to \$41.00

Financial news for CPHD dated on 2013-08-28: Cepheid Reports Xpert MTB/RIF Categorized 'Moderate Complexity' by FDA

Financial news for CPHD dated on 2013-07-25: Cepheid Wins FDA Marketing Authorization for Xpert MTB-RIF Assay

Financial news for CPHD dated on 2013-07-22: Market Wrap for Monday, July 22: Stocks Rise Slightly in Quiet Trade

Financial news for CPHD dated on 2013-07-19: UPDATE: Piper Jaffray Upgrades Cepheid Following In-Line 2Q13 Results

Financial news for CPHD dated on 2013-07-19: Piper Jaffray Upgrades CEPHEID to Overweight, Raises PT to \$43.00

Financial news for CPHD dated on 2013-07-11: Cepheid Reports Prelim. Q2 Adj. EPS \$0.02 vs \$0.03/Share Loss Est, Sales ~\$96M vs \$92.2M Est; COO, Head of US Manufacturing Operations to Leave Co.

Financial news for CPHD dated on 2013-06-27: Cepheid Receives FDA Clearance For Updated Xpert MRSA/SA Blood Culture (BC) Test

Financial news for CPHD dated on 2013-06-26: Oppenheimer Assumes CEPHEID at Outperform, Announces \$41.00 PT

Financial news for CPHD dated on 2013-06-11: FDA Issues Report for June 13th Panel Meeting on Flu Tests

Financial news for CPHD dated on 2013-06-03: Craig-Hallum Downgrades CEPHEID to Hold, Lowers PT to \$35.00

Financial news for CPHD dated on 2013-05-31: UPDATE: Jefferies Assumes Coverage on Cepheid, Downgrades to Hold on Valuation

Financial news for CPHD dated on 2013-05-31: UPDATE: Jefferies Downgrades Cepheid to Hold on Persistent Volatility

Financial news for CPHD dated on 2013-05-31: Jefferies Downgrades CEPHEID to Hold, Announces \$38.00 PT

Financial news for CPHD dated on 2013-04-19: UBS Maintains Buy on CEPHEID, Raises PT to \$42.00

Financial news for CPHD dated on 2013-04-19: Wedbush Maintains Outperform on CEPHEID, Raises PT to \$40.00

Financial news for CPHD dated on 2013-04-19: Oppenheimer Maintains Outperform on CEPHEID, Raises PT to \$41.00

Financial news for CPHD dated on 2013-04-19: Cantor Fitzgerald Maintains Hold on CEPHEID, Raises PT to \$40.00

Financial news for CPHD dated on 2013-04-18: CEPHEID Sees FY2013 EPS \$(0.05)-0.01 vs \$0.02 Est; Sees Sales \$375.0M-385.0M vs \$381.28M Est

Financial news for CPHD dated on 2013-04-18: Benzinga's Top Initiations

Financial news for CPHD dated on 2013-04-18: Citigroup Initiates Coverage on CEPHEID at Neutral, Announces \$40.00 PT

Financial news for CPHD dated on 2013-02-14: Cepheid Announces Board of Directors Changes

Financial news for CPHD dated on 2013-01-25: UBS Maintains Buy on CEPHEID, Lowers PT to \$40.00

Financial news for CPHD dated on 2013-01-24: CEPHEID Reports Q4 Non-GAAP EPS of \$0.20; Revenue of \$89.70M

Financial news for CPHD dated on 2013-01-24: CEPHEID Reports Q4 EPS of \$0.08

Financial news for CPHD dated on 2013-01-15: Cepheid's Chlamydia and N. Gonorrhoeae Test Categorized 'Moderate Complexity' by FDA

Financial news for CPHD dated on 2013-01-08: Cepheid Offers Update on Xpert Test Availability, Sees Q4 Sales ~\$92M vs \$93.5M Est, EPS \$0.10-0.12

Financial news for CPHD dated on 2013-01-04: UPDATE: Piper Jaffray Downgrades Cepheid to Neutral, Lowers PT

Financial news for CPHD dated on 2013-01-04: Benzinga's Top Downgrades

Financial news for CPHD dated on 2013-01-04: Piper Jaffray Downgrades CEPHEID to Neutral, Lowers PT to \$34.00

Financial news for CPHD dated on 2012-12-28: Oppenheimer Holdings Reiterates Outperform Rating, \$43 PT on Cepheid

Financial news for CPHD dated on 2012-12-28: Canaccord Genuity Reiterates Buy Rating, \$50 PT on Cepheid

Financial news for CPHD dated on 2012-12-28: Cantor Fitzgerald Reiterates Hold Rating, \$38 PT on Cepheid

Financial news for CPHD dated on 2012-12-28: US Stock Futures Down Ahead Of Economic Data

Financial news for CPHD dated on 2012-12-28: Stocks To Watch For December 28, 2012

Financial news for CPHD dated on 2012-12-27: UPDATE: Cepheid Wins FDA Clearance for Xpert CT/NG

Financial news for CPHD dated on 2012-12-27: Cepheid Receives FDA Clearance for Xpert CT/NG

Financial news for CPHD dated on 2012-12-17: UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, Platform

Financial news for CPHD dated on 2012-12-17: Bank of America Initiates Coverage on CEPHEID at Buy, Announces \$40.00 PO

Financial news for CPHD dated on 2012-11-19: UPDATE: Goldman Sachs Downgrades Cepheid to Neutral on Lack of Catalysts

Financial news for CPHD dated on 2012-11-19: Goldman Sachs Downgrades Cepheid from

Buy to Neutral, Announces PT of \$32

Financial news for CPHD dated on 2012-11-19: Goldman Sachs Downgrades Cepheid from Buy to Neutral, Announces PT of \$32

Financial news for CPHD dated on 2012-11-19: Benzinga's Top Downgrades

Financial news for CPHD dated on 2012-11-16: Benzinga's Top Upgrades

Financial news for CPHD dated on 2012-11-05: Craig-Hallum Initiated Coverage on Cepheid at Buy, Announced PT to \$42

Financial news for CPHD dated on 2012-10-19: Jefferies & Company Maintains Cepheid at Buy, Lowers PT from \$42 to \$38

Financial news for CPHD dated on 2012-10-18: Cepheid Reports Q3 EPS \$0.01 vs \$-0.06 Est; Revenues \$80.5M vs \$80.96M Est

Financial news for CPHD dated on 2012-10-02: Cowen Initiates Coverage Cepheid at Outperform

Financial news for CPHD dated on 2012-09-28: UPDATE: Cantor Fitzgerald Maintains Cepheid at Hold on Analyst Day Takeaways

Financial news for CPHD dated on 2012-09-28: UPDATE: Canaccord Genuity Reiterates Cepheid at Buy with \$50 PT Post Analyst Day

Financial news for CPHD dated on 2012-09-28: Goldman Sachs Reiterates Buy Rating, \$46 PT on Cepheid

Financial news for CPHD dated on 2012-09-28: UPDATE: ISI Group Reduces PT to \$30.50 on Cepheid Post Analyst Day

Financial news for CPHD dated on 2012-09-28: ISI Group Maintains Cepheid at Underweight, Lowers PT from \$32.50 to \$30.50

Financial news for CPHD dated on 2012-09-27: Benzinga Mid-Afternoon Market Update

Financial news for CPHD dated on 2012-09-27: Benzinga Mid-Day Market Update

Financial news for CPHD dated on 2012-09-27: Mid-Morning Market Update

Financial news for CPHD dated on 2012-09-27: Cepheid on Analyst Webcast, Says Sees Expansion in Current Markets; Has \$5M+ in Backlog to be Shipped

Financial news for CPHD dated on 2012-09-27: UPDATE: ISI Group Reduces PT to \$32.50 on Cepheid Following Negative Pre-Announcement

Financial news for CPHD dated on 2012-09-27: ISI Group Maintains Cepheid at Underweight, Lowers PT from \$35 to \$32.50

Financial news for CPHD dated on 2012-09-26: Cepheid Guides Q3 Revenue \$79-81M, Had Seen \$84-86M vs \$83.8M Est

Financial news for CPHD dated on 2012-09-26: Benzinga's Top Initiations

Financial news for CPHD dated on 2012-09-26: A Peek Into The Market Before The Trading Starts

Financial news for CPHD dated on 2012-09-26: UPDATE: JP Morgan Initiates Cepheid at Overweight on Growth Outlook

Financial news for CPHD dated on 2012-09-26: JP Morgan Initiates Coverage on Cepheid at Overweight, Announces PT of \$47

Financial news for CPHD dated on 2012-08-30: UPDATE: Cantor Fitzgerald Initiates Cepheid to Hold with \$40 PT on Full Valuation

Financial news for CPHD dated on 2012-08-30: Benzinga's Top Initiations

Financial news for CPHD dated on 2012-08-30: Cantor Fitzgerald Initiates Coverage on Cepheid at Hold, Announces PT of \$40

Financial news for CPHD dated on 2012-07-20: Cepheid Down 20% on Weak Guidance

Financial news for CPHD dated on 2012-07-20: UBS Maintains Cepheid at Buy, Lowers PT from \$45 to \$43

Financial news for CPHD dated on 2012-07-20: UPDATE: Wedbush Lowers its PT on Cepheid

from \$45 to \$42

Financial news for CPHD dated on 2012-07-20: Wedbush Securities Maintains Cepheid at Outperform, Lowers PT from \$45 to \$42

Financial news for CPHD dated on 2012-07-19: UPDATE: Cepheid Says It Is Distinct Possibility Revenue Could be at Lower End

Financial news for CPHD dated on 2012-07-19: UPDATE: Cepheid Says Near Term Uncertainties for Customers

Financial news for CPHD dated on 2012-07-19: UPDATE: Cepheid Guides FY EPS \$0.0-0.04, Had Seen \$0.12-0.17 vs \$0.14 Est

Financial news for CPHD dated on 2012-07-19: UPDATE: Cepheid Guides FY EPS \$0-0.04 vs \$0.14 Est

Financial news for CPHD dated on 2012-07-19: Cepheid Reports Q2 EPS \$0.02 vs \$0.02 Est; Revenues \$81M vs \$82.67M Est

Financial news for CPHD dated on 2012-07-10: UPDATE: ISI Group Initiates Cepheid with Underweight, \$47 PT on Unfavorable Risk/Reward

Financial news for CPHD dated on 2012-07-10: ISI Group Initiates Coverage on Cepheid at Underweight, Announces PT of \$47

Financial news for CPHD dated on 2012-05-24: Financial Breakfast: Morning News Summary for May 24, 2012

Financial news for CPHD dated on 2012-05-24: A Peek Into The Market Before The Trading Starts

Financial news for CPHD dated on 2012-05-24: Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay

Financial news for CPHD dated on 2012-05-15: UPDATE: UBS Investment Research Upgrades Cepheid to Buy; Opportunistic Inflection

Financial news for CPHD dated on 2012-05-15: UBS Upgrades Cepheid from Neutral to Buy, Raises PT from \$44 to \$45

Financial news for CPHD dated on 2012-05-14: Benzinga's Top Downgrades With Color for May 14, 2012

Financial news for CPHD dated on 2012-05-14: UPDATE: GARP Research & Securities Downgrades Cepheid to Neutral; Valuation Full

Financial news for CPHD dated on 2012-05-14: GARP Research Downgrades Cepheid from Buy to Neutral, Announces PT of \$38

Financial news for CPHD dated on 2012-05-14: GARP Research Downgrades Cepheid from Buy to Neutral, Announces PT of \$38

Financial news for CPHD dated on 2012-04-20: UBS Maintains Cepheid at Neutral, Lowers PT from \$45 to \$44

Financial news for CPHD dated on 2012-04-19: Cepheid Guides FY EPS \$0.50-0.55, Had Seen \$0.55-0.60 vs \$0.56 Est

Financial news for CPHD dated on 2012-04-19: Cepheid Reports Q1 EPS \$-0.02 vs \$-0.02 Est; Revenues \$60.2M vs \$77.16M Est

Financial news for CPHD dated on 2012-03-20: Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria

Financial news for CPHD dated on 2012-01-27: Cepheid Up 19% After Positive Earnings Report

Financial news for CPHD dated on 2012-01-26: Cepheid Trades 18% Higher on Earnings Beat

Financial news for CPHD dated on 2012-01-26: Cepheid Reports Q4 EPS \$0.14 vs \$0.01 Est; Revenues \$80.10M vs \$73.70M Est

Financial news for CPHD dated on 2012-01-06: RBC Capital Upgrades Cepheid to Outperform

Financial news for CPHD dated on 2011-12-15: UPDATE: Credit Suisse Initiates Outperform, \$40 Target on Cepheid

Financial news for CPHD dated on 2011-12-07: Analogic Earnings Preview: EPS Expected to Double

Financial news for CPHD dated on 2011-11-28: Oppenheimer Names Cepheid on December's Top Ideas

Financial news for CPHD dated on 2011-11-17: Wedbush Maintains Outperform Rating and \$43 PT on Cepheid

Financial news for CPHD dated on 2011-11-17: Oppenheimer Reiterates Outperform, \$42 PT on Cepheid

Financial news for CPHD dated on 2011-10-21: UPDATE: Jefferies Raises PT to \$42 on Cepheid

Financial news for CPHD dated on 2011-10-21: UPDATE: Oppenheimer Raises PT on Cepheid to \$42

Financial news for CPHD dated on 2011-10-21: UPDATE: Piper Jaffray Lower PT to \$38 on Cepheid

Financial news for CPHD dated on 2011-10-21: Jefferies Raises PT On Cepheid to \$42

Financial news for CPHD dated on 2011-10-21: Goldman Sachs Raises PT on Cepheid to \$46

Financial news for CPHD dated on 2011-10-20: Cepheid Sees Year End EPS \$0.03 vs \$0.03 Est; Revenues \$269M-\$272M vs \$268.83M Est

Financial news for CPHD dated on 2011-10-20: Cepheid Reports Q3 EPS \$0.03 vs \$0.02 Est; Revenues \$70.2M vs \$68.26M Est

Financial news for CPHD dated on 2011-09-23: Goldman Sachs Upgrades Cepheid to Buy

Financial news for CPHD dated on 2011-08-30: Wedbush Reaffirms Outperform on Cepheid

Financial news for CPHD dated on 2011-08-30: Wedbush Adds Cepheid To Best Ideas List

Financial news for CPHD dated on 2011-08-09: Cepheid Announces Release of Updated Xpert BCR-ABL Monitor Test

Financial news for CPHD dated on 2011-08-01: Defense and Security Stocks Trading Alert: Aerosonic, Kratos Defense & Security, Visualant, Irvine Sensors

Financial news for CPHD dated on 2011-07-27: Piper Jaffray Rates CPHD

Financial news for CPHD dated on 2011-07-22: Cepheid up Nearly 22% on Better Than Expected Earnings

Financial news for CPHD dated on 2011-07-22: Pre-Market Winners

Financial news for CPHD dated on 2011-07-22: UPDATE: Piper Jaffray Raises PT on Cepheid to \$39

Financial news for CPHD dated on 2011-07-22: Piper Jaffray Raises PT On Cepheid To \$39

Financial news for CPHD dated on 2011-07-21: After Hours Earnings Movers